Garavaglia Beatrice, Vallino Letizia, Ferraresi Alessandra, Visciglia Annalisa, Amoruso Angela, Pane Marco, Munteanu Camelia, Isidoro Ciro
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale, Via P. Solaroli 17, 28100 Novara, Italy.
Probiotical Research Srl, Via E. Mattei 3, 28100 Novara, Italy.
Biomedicines. 2025 Jun 25;13(7):1554. doi: 10.3390/biomedicines13071554.
Colorectal cancer (CRC) is a major global health concern, particularly in Western countries where there is high consumption of processed food. Gut microbiota, intestinal inflammation, and autophagy play pivotal roles in CRC initiation and progression. Probiotics and probiotic metabolites (particularly short-chain fatty acids) have emerged as potential preventive and adjuvant therapeutics by restoring a balanced gut microbiota, dampening inflammation, stimulating immune response, and improving barrier integrity and intestinal epithelial homeostasis by modulating autophagy. This narrative review discusses the current evidence supporting the anti-inflammatory, immunomodulatory, and pro-autophagy effects of probiotics and their metabolites and explores their potential preventive and therapeutic applications in CRC management.
结直肠癌(CRC)是一个重大的全球健康问题,尤其是在加工食品消费量高的西方国家。肠道微生物群、肠道炎症和自噬在结直肠癌的发生和发展中起关键作用。益生菌和益生菌代谢产物(特别是短链脂肪酸)已成为潜在的预防和辅助治疗手段,通过恢复肠道微生物群平衡、减轻炎症、刺激免疫反应以及通过调节自噬改善屏障完整性和肠道上皮稳态。这篇叙述性综述讨论了支持益生菌及其代谢产物的抗炎、免疫调节和促自噬作用的现有证据,并探讨了它们在结直肠癌管理中的潜在预防和治疗应用。